Neoadjuvant immune combination therapy for muscle-invasive bladder cancer
10.3760/cma.j.cn112330-20210430-00245
- VernacularTitle:新辅助免疫联合用于治疗肌层浸润性膀胱癌的研究进展
- Author:
Guowei FENG
1
;
Ge SONG
;
Zhenting ZHANG
;
Kun WANG
;
Xin YAO
Author Information
1. 天津医科大学肿瘤医院泌尿肿瘤科 国家肿瘤临床医学研究中心 天津市肿瘤防治重点实验室 天津市恶性肿瘤临床医学研究中心，天津 300060
- Keywords:
Urinary bladder neoplasms;
Muscle-invasive bladder cancer;
Immune checkpoint inhibitor;
Neoadjuvant therapy;
Immunotherapy
- From:
Chinese Journal of Urology
2022;43(4):309-312
- CountryChina
- Language:Chinese
-
Abstract:
Neoadjuvant therapy leads to the eradication of micrometastasis, thereby providing survival benefit to patients with muscle-invasive bladder cancer (MIBC). In the recent years, multiple clinical trials have corroborated the safety and durability of immune checkpoint inhibitors in the treatment of MIBC. Notably, there is a significantly higher response rate (e.g. pathologic complete response) and comparable occurrence of adverse events in patients treated with neoadjuvant dual immunotherapy, immunotherapy combined with chemotherapy or targeted therapy as compared with that treated with neoadjuvant single-agent immunotherapy. With an overview of breakthroughs in the past years, we believe that immune combination therapy is of great promise and expected to revolutionize the landscape of neoadjuvant therapy of MIBC.
